Compound ID | 153
CAL02
Class: Nanoparticles (liposomes)
| Spectrum of activity: | Gram-positive |
| Details of activity: | Liposomes could be used for the treatment of antibiotic-resistant bacterial pathogens, because they neutralize the bacterial toxins and allow time for the host immune system to eliminate the bacteria. E.g. S.aureus |
| Combined with other compounds: | Yes |
| Institute where first reported: | LASCCO, Switzerland |
| Year first mentioned: | 2013 |
| Highest developmental phase: | Phase 2 (NCT05776004) |
| Development status: | Active (as of 2025) |
| External links: | |
| Citations: |
|
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.